- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12.24 | HilleVax, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.24 | HilleVax GAAP EPS of -$0.52 misses by $0.10 | 2 | Seeking Alpha | ||
| 07.11.24 | HilleVax, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.11.24 | HilleVax, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10.24 | HilleVax kündigt Personalabbau zur Kostensenkung an | 2 | Investing.com Deutsch | ||
| 16.10.24 | HilleVax announces workforce reduction to cut costs | 2 | Investing.com | ||
| 16.10.24 | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.08.24 | HilleVax GAAP EPS of -$0.83 | 1 | Seeking Alpha | ||
| HILLEVAX Aktie jetzt für 0€ handeln | |||||
| 09.08.24 | HilleVax, Inc.: HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress | 197 | GlobeNewswire (Europe) | $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine... ► Artikel lesen | |
| 01.08.24 | HilleVax slashes workforce by 40% after norovirus vaccine trial failure | 1 | Pharmaceutical Technology | ||
| 01.08.24 | HilleVax Lays Off 40% of Workforce | 1 | Contract Pharma | ||
| 01.08.24 | UniQure, Arbutus and HilleVax all lay off staff as biotechs streamline operations and cut costs | 4 | FierceBiotech | ||
| 31.07.24 | HilleVax, Inc.: HilleVax Announces Reduction in Force | 111 | GlobeNewswire (Europe) | BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce... ► Artikel lesen | |
| 31.07.24 | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07.24 | HilleVax, Inc.: HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants | 288 | GlobeNewswire (Europe) | The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential... ► Artikel lesen | |
| 20.03.24 | HilleVax, Inc.: HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress | 123 | GlobeNewswire (Europe) | Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,165 | +3,22 % | Evotec: Diese Supportzone darf nicht fallen | Die Befürchtung, dass der abrupte Abgang des langjährigen Vorstandschefs Langthaler vor gut einem Jahr problematisch würde, hat sich bestätigt. Evotec sortiert sich neu, das braucht Zeit und ist ergebnisoffen.... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | 0,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
| PALATIN TECHNOLOGIES | 0,932 | +2,98 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,130 | +0,73 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| GALAPAGOS NV | 22,660 | +0,27 % | Galapagos inks agreement with Catalent for experimental CAR-T therapy | ||
| CENTOGENE | 0,120 | +20,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| AFFIMED | 1,060 | +1,92 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,230 | -6,50 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| COHERUS | 1,196 | +1,61 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,492 | -4,65 % | Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones | - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| AC IMMUNE | 2,640 | +2,13 % | AC Immune SA: AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious... ► Artikel lesen | |
| CHIMERIX | 3,670 | -2,91 % | Chimerix, Inc.: Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 0,880 | +2,92 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update | - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated... ► Artikel lesen |
Das Unternehmen HILLEVAX INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,03 % bei einem Aktienkurs von 1,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HILLEVAX INC finden Sie auf Wallstreet Online.
